Influenza B Victoria lineage egg-derived candidate vaccine ...

Influenza B Victoria lineage egg-derived1 candidate vaccine viruses for development and production of vaccines for use in the 2020-2021 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed twoway haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country.2

28 February 2020 (Last updated on 12 June 2020)

Candidate vaccine viruses (antigenically like B/Washington/02/2019)

Parent virus B/Hong Kong/574/2019 B/Washington/02/2019

Candidate Type of virus or Developing vaccine virus reassortant institute

Wild type virus

BX-87C*

Classical

NYMC

Wild type virus

BX-85C

Classical

NYMC

Available from

WHO CCs

NYMC, USA

WHO CCs NIBSC, UK NYMC, USA NIBSC, UK

B/Brisbane/35/2018

Wild type virus

NIBSC, UK

B/Victoria/705/2018

B/Sichuan-Gaoxin/531/2018 * New CVV

Wild type virus

BVR-11

Classical

Wild type virus

BX-83A

Classical

CNIC-1906

Classical

VIDRL

NIBSC, UK

CCDC, China FCI, UK

NIBSC, UK NIID, Japan VIDRL, Australia

NYMC CCDC

CCDC, China NYMC, USA

CCDC, China FCI, UK

NIBSC, UK NIID, Japan VIDRL, Australia

1 For cell-derived candidate vaccine viruses and reference reagents please see 2

Page 1 of 3

Institutes contact details for candidate vaccine viruses orders/information:

CCDC:

whocc-china@.cn

CDC:

dwentworth@ (Subject: CVV request)

FCI:

whocc@crick.ac.uk

NIBSC: standards@ or enquiries@

NIID:

flu-vaccine@nih.go.jp

NYMC: doris_bucher@nymc.edu

VIDRL: whoflu@

WHO CCs:

Reference antigens (freeze-dried)

Parent virus

Starting materials

Candidate vaccine virus

Egg or cell

B/Washington/02/2019 Wild type

Egg

B/Victoria/705/2018

BVR-11

Egg

B/Darwin/7/2019 * new reagents

Cell Wild type

Cell

Ref Ag

Unitage

Lot number (?g HA/ml)

19/190

52 ?g/ml

B(v)-Ag-1912 19/238 19/208

77 ?g/ml 76 ?g/ml 79 ?g/ml

2019/130B 89 ?g/ml

B(v)-Ag-2002*

19/210

41 ?g/vial

44 ?g/ml

Available from

NIBSC, UK

CBER/FDA, USA

NIBSC, UK

NIBSC, UK

TGA, Australia CBER/FDA,

USA NIBSC, UK

Sheep antisera

Purified HA from Parent virus

B/Washington/02/2019 ? like

Egg or Cell Egg

Order Lot number

19/218 B(v)-Ab-1914

AS436

Available from

NIBSC, UK CBER/FDA, USA TGA, Australia

The above-listed potency testing reagents have been developed with support from manufacturers, and calibrated by the WHO Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS).

ERLs contact details for reagents orders/information:

CBER/FDA: CBERShippingRequests@fda.

NIBSC:

standards@ or enquiries@

NIID:

flu-vaccine@nih.go.jp

Page 2 of 3

TGA:

influenza.reagents@.au

The list of all WHO Collaborating Centres (CCs) and Essential Regulatory Laboratories (ERLs) for influenza can be found on the WHO web site at

For other candidate vaccine viruses and potency testing reagents, please go to

For general enquiries, please contact gisrs-whohq@who.int

Page 3 of 3

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download